Artera's AI Platform Advances Personalized Prostate Cancer Treatment at 2025 ASCO Annual Meeting

Artera, a precision medicine company based in San Francisco, is set to present groundbreaking validation data for its Multimodal Artificial Intelligence (MMAI) platform at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Two significant abstracts will be highlighted, including an oral presentation selected for Best of ASCO 2025, a distinction reserved for the most impactful studies in cancer care. The oral presentation focuses on the development and validation of Artera's first MMAI algorithm, the ArteraAI Prostate Test, which identifies high-risk, non-metastatic prostate cancer patients who would benefit from adding androgen receptor pathway inhibitors (ARPIs) to their standard therapy. The STAMPEDE trial, a large-scale study, found that ARPIs, particularly abiraterone acetate + prednisolone, significantly improve outcomes for certain high-risk patients. However, the adoption of ARPIs has been inconsistent, often due to hesitations about side effects and follow-up care. Artera's model addresses this issue by pinpointing the 25% of high-risk patients who gain substantial benefits from ARPIs, potentially sparing 75% of this patient group from unnecessary and harmful treatments. Nick James, MD, PhD, a leading professor in Prostate and Bladder Cancer Research at The Institute of Cancer Research, London, and a Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust, emphasized the importance of this data. "This study answers a crucial question in cancer care: which patients will benefit from additional treatment, and which will not," he stated. Traditional methods can identify high-risk patients but struggle to tailor specific therapies. Artera's AI tool can uncover hidden patterns and optimize treatment plans, ensuring that only those who truly need ARPIs receive them, thus avoiding unnecessary side effects and potential lethal consequences. Artera's second presentation, a poster session, delves into the external validation of its MMAI platform for predicting outcomes in men who have undergone radical prostatectomy (RP) for localized prostate cancer. The research confirms that the RP MMAI model is an independent prognostic tool, effectively predicting biochemical recurrence (BCR) and long-term outcomes. Notably, Artera's solution utilizes routine pathology and clinical data, eliminating the need for additional tissue samples or complex molecular tests. This makes the platform highly scalable, cost-effective, and quick to implement. Timothy Showalter, Chief Medical Officer of Artera, expressed pride in the company's achievements. "We are honored to have two abstracts accepted at ASCO 2025, especially an oral presentation for Best of ASCO," he said. "These studies validate our commitment to providing clinicians and patients with personalized, actionable insights. They demonstrate that our MMAI platform can enhance the precision and effectiveness of prostate cancer care by enabling data-driven, shared decision-making." The presentations will be part of the 2025 ASCO Annual Meeting in Chicago. The oral presentation, titled "Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE," is scheduled for Tuesday, June 3rd at 9:45 a.m. CT. The poster presentation, "External validation of a pathology-based multimodal artificial intelligence biomarker for predicting prostate cancer outcomes after prostatectomy," will take place on Monday, June 2nd at 9:00 a.m. CT. Industry insiders view Artera’s contributions as a significant step forward in the field of personalized cancer care. By integrating AI with existing clinical workflows, Artera is democratizing access to advanced diagnostics and treatment planning. This approach not only improves patient outcomes but also reduces healthcare costs and enhances the quality of life for patients. The validation of Artera's MMAI platform in multiple clinical settings underscores its potential to transform how cancer is managed and treated. Artera, founded with a mission to revolutionize cancer care through precision medicine, operates a CLIA-certified and College of American Pathologists (CAP) accredited laboratory in Jacksonville, Florida. The company's flagship product, the ArteraAI Prostate Test, is already clinically available and can be ordered online, providing both prognostic and predictive insights for localized prostate cancer patients. With ongoing research and clinical validations, Artera is poised to continue expanding its impact in the oncology field, offering hope and better care for individuals battling cancer.